MR
MROPF.US MicroPort CardioFlow Medtech Corporation
- Market cap
- USD 823M
- P/E
- -
- P/B
- 1.04x
- ROE
- -7.3%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the fiscal year ending Dec 2025.
Is MROPF.US undervalued?
Graham numberThe Graham number of MicroPort CardioFlow Medtech Corporation cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
MicroPort CardioFlow Medtech Corporation fundamental analysis
No fundamental analysis for MicroPort CardioFlow Medtech Corporation yet.
MicroPort CardioFlow Medtech Corporation stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About MicroPort CardioFlow Medtech Corporation
MicroPort CardioFlow Medtech Corporation, together with its subsidiaries, researches, develops, manufactures, and sells medical devices for the treatment of structural heart disease and cardiac rhythm management in China, Europe, the Middle East, Africa, Asia, North America, and internationally. The company offers VitaFlow, a transcatheter aortic valve system; VitaFlow Liberty, a transcatheter aortic valve retrievable and controllable bend delivery system; Alwide, a plus val…
Full company profileMicroPort CardioFlow Medtech Corporation financial statements
MicroPort CardioFlow Medtech Corporation annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Income Statement | ||||||
| Revenue | 104M | 201M | 36.4M | 47.4M | 50.8M | 57.0M |
| Gross Profit | 45.4M | 119M | 23.5M | 32.4M | 35.3M | 37.1M |
| Operating Income | -185M | -203M | -48.1M | -49.6M | -22.4M | -20.5M |
| EBITDA | - | - | -53.3M | -54.5M | 6.30M | -2.21M |
| Net Income | -398M | -183M | -65.9M | -66.5M | -6.95M | -18.8M |
| EPS | -0.17 | -0.08 | -0.03 | -0.03 | 0.00 | -0.01 |
| Balance Sheet | ||||||
| Total Assets | 1.11B | 3.36B | 3.00B | 2.58B | 2.68B | 670M |
| Total Liabilities | 1.46B | 266M | 248M | 242M | 454M | 413M |
| Shareholders' Equity | -345M | 3.10B | 2.75B | 2.33B | 2.22B | 256M |
| Cash & Short-term Investments | 612M | 2.21B | 1.87B | 1.07B | 108M | 69.6M |
| Cash Flow | ||||||
| Operating Cash Flow | -110M | -162M | -183M | -207M | -112M | -3.32M |
| Capital Expenditure | 58.2M | 108M | 49.1M | 30.5M | 158M | 34.9M |
| Free Cash Flow | -168M | -270M | -232M | -238M | -270M | -38.3M |
| Ratios | ||||||
| ROE | - | -5.9% | -2.4% | -2.8% | -0.3% | -7.3% |
| ROA | -35.8% | -5.5% | -2.2% | -2.6% | -0.3% | -2.8% |
| Net Profit Margin | -383.0% | -91.3% | -181.0% | -140.2% | -13.7% | -33.0% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
MicroPort CardioFlow Medtech Corporation dividends
MicroPort CardioFlow Medtech Corporation has not paid dividends in the last 6 fiscal years.
Last stock split: 1:5 on Feb 24, 2026.
Who owns MicroPort CardioFlow Medtech Corporation
- Insiders 48.98%
- Institutions 20.93%
- Public & others 30.10%
- Shares outstanding 1.27B
- Free float 447M
MicroPort CardioFlow Medtech Corporation company profile
- Company name
- MicroPort CardioFlow Medtech Corporation
- Ticker
- MROPF.US
- Exchange
- USA Stocks
- Sector
- Healthcare
- Industry
- Medical Devices
- Employees
- 1,415
- Fiscal year end
- December
- Address
- No. 501 Niudun Road, Shanghai, China
- Phone
- 86 21 3895 4600
- Website
- cardioflowmedtech.com
About MicroPort CardioFlow Medtech Corporation
MicroPort CardioFlow Medtech Corporation, together with its subsidiaries, researches, develops, manufactures, and sells medical devices for the treatment of structural heart disease and cardiac rhythm management in China, Europe, the Middle East, Africa, Asia, North America, and internationally. The company offers VitaFlow, a transcatheter aortic valve system; VitaFlow Liberty, a transcatheter aortic valve retrievable and controllable bend delivery system; Alwide, a plus valve balloon dilation catheter; AccuSniper, a double-layer balloon dilation catheter, Angelguide, an advanced pre-shaped ultra-hard guidewire; and AnchorMan, a left atrial appendage occlusion and guidance system. It also provides various active, mitral, and tricuspid valve products; left atrial appendage closure products; surgical accessories; low and high-voltage CRM products; leads and accessories; patient monitoring products; and arrhythmia diagnostic devices. In addition, the company offers clinical solutions, including aortic stenosis and atrial fibrillation-related stroke prevention. Further, it is involved in the manufacturing of raw materials for medical devices treating valvular heart diseases; and properties management. The company was founded in 2009 and is headquartered in Shanghai, China.
MicroPort CardioFlow Medtech Corporation management
8- Mr. Guoming ChenCEO & Executive Director · born 1985
- Mr. Ruinian ZhangPresident & Executive Director · born 1964
- Mr. Paul VoddenChief Financial Officer · born 1966
- Mr. Xiaoming ZhuChief Operating Officer · born 1968
- Ms. Alice FlaccoExecutive VP & General Counsel · born 1985
- Mr. Hugues GervaisChief Commercial Officer
- Ms. Xiangmei LiJoint Company Secretary
- Ms. Lok Yee Chan A.C.I.S., A.C.S.Joint Company Secretary · born 1990